These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33527340)

  • 21. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
    Ataga KI; Smith WR; De Castro LM; Swerdlow P; Saunthararajah Y; Castro O; Vichinsky E; Kutlar A; Orringer EP; Rigdon GC; Stocker JW;
    Blood; 2008 Apr; 111(8):3991-7. PubMed ID: 18192510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KCa 3.1-a microglial target ready for drug repurposing?
    Dale E; Staal RG; Eder C; Möller T
    Glia; 2016 Oct; 64(10):1733-41. PubMed ID: 27121595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.
    Tubman VN; Mejia P; Shmukler BE; Bei AK; Alper SL; Mitchell JR; Brugnara C; Duraisingh MT
    Antimicrob Agents Chemother; 2016 Jan; 60(1):613-6. PubMed ID: 26459896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two drugs for sickle cell disease.
    Med Lett Drugs Ther; 2020 Apr; 62(1595):51-52. PubMed ID: 32324178
    [No Abstract]   [Full Text] [Related]  

  • 25. An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'.
    Inusa BPD; Mnika K; Babiker S
    Expert Rev Hematol; 2023; 16(8):585-591. PubMed ID: 37329253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
    Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
    Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease.
    Jin LW; Lucente JD; Nguyen HM; Singh V; Singh L; Chavez M; Bushong T; Wulff H; Maezawa I
    Ann Clin Transl Neurol; 2019 Apr; 6(4):723-738. PubMed ID: 31019997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
    Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM
    Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical trials of new therapeutic pharmacology for sickle cell disease].
    Brugnara C; de Franceschi L
    Sante; 2006; 16(4):263-8. PubMed ID: 17446160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Senicapoc: a potent candidate for the treatment of a subset of hereditary xerocytosis caused by mutations in the Gardos channel.
    Rapetti-Mauss R; Soriani O; Vinti H; Badens C; Guizouarn H
    Haematologica; 2016 Nov; 101(11):e431-e435. PubMed ID: 27443288
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
    Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data.
    Estepp JH
    Am J Hematol; 2018 Mar; 93(3):326-329. PubMed ID: 29352729
    [No Abstract]   [Full Text] [Related]  

  • 33. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.
    Paka L; Smith DE; Jung D; McCormack S; Zhou P; Duan B; Li JS; Shi J; Hao YJ; Jiang K; Yamin M; Goldberg ID; Narayan P
    World J Gastroenterol; 2017 Jun; 23(23):4181-4190. PubMed ID: 28694658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Senicapoc: Repurposing a Drug to Target Microglia K
    Staal RGW; Weinstein JR; Nattini M; Cajina M; Chandresana G; Möller T
    Neurochem Res; 2017 Sep; 42(9):2639-2645. PubMed ID: 28364331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
    McNaughton-Smith GA; Burns JF; Stocker JW; Rigdon GC; Creech C; Arrington S; Shelton T; de Franceschi L
    J Med Chem; 2008 Feb; 51(4):976-82. PubMed ID: 18232633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How do we monitor hemoglobin S in patients who undergo red blood cell exchange and take voxelotor?
    Godbey EA; Anderson MR; M Bachmann L; Sanford KW; Wieditz K; Roseff SD
    Transfusion; 2021 Jun; 61(6):1680-1683. PubMed ID: 33880770
    [No Abstract]   [Full Text] [Related]  

  • 37. Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease.
    Çanak B; Eşkazan AE
    Br J Clin Pharmacol; 2022 Jun; 88(6):2564-2565. PubMed ID: 35158414
    [No Abstract]   [Full Text] [Related]  

  • 38. An update review of new therapies in sickle cell disease: the prospects for drug combinations.
    Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD
    Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating sickle cell anemia: A new era dawns.
    Steinberg MH
    Am J Hematol; 2020 Apr; 95(4):338-342. PubMed ID: 31925819
    [No Abstract]   [Full Text] [Related]  

  • 40. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice.
    Stocker JW; De Franceschi L; McNaughton-Smith GA; Corrocher R; Beuzard Y; Brugnara C
    Blood; 2003 Mar; 101(6):2412-8. PubMed ID: 12433690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.